HLVX vs. ITOS, RVNC, FULC, CKPT, VIGL, RZLT, ARCT, ADCT, RAPP, and MREO
Should you be buying HilleVax stock or one of its competitors? The main competitors of HilleVax include iTeos Therapeutics (ITOS), Revance Therapeutics (RVNC), Fulcrum Therapeutics (FULC), Checkpoint Therapeutics (CKPT), Vigil Neuroscience (VIGL), Rezolute (RZLT), Arcturus Therapeutics (ARCT), ADC Therapeutics (ADCT), Rapport Therapeutics (RAPP), and Mereo BioPharma Group (MREO). These companies are all part of the "pharmaceutical products" industry.
HilleVax vs.
iTeos Therapeutics (NASDAQ:ITOS) and HilleVax (NASDAQ:HLVX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, community ranking, institutional ownership and valuation.
iTeos Therapeutics' return on equity of -20.11% beat HilleVax's return on equity.
iTeos Therapeutics has a beta of 1.51, suggesting that its share price is 51% more volatile than the S&P 500. Comparatively, HilleVax has a beta of 0.74, suggesting that its share price is 26% less volatile than the S&P 500.
97.2% of iTeos Therapeutics shares are owned by institutional investors. Comparatively, 86.4% of HilleVax shares are owned by institutional investors. 12.5% of iTeos Therapeutics shares are owned by company insiders. Comparatively, 24.9% of HilleVax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
iTeos Therapeutics received 39 more outperform votes than HilleVax when rated by MarketBeat users. Likewise, 73.13% of users gave iTeos Therapeutics an outperform vote while only 55.56% of users gave HilleVax an outperform vote.
iTeos Therapeutics has higher revenue and earnings than HilleVax. iTeos Therapeutics is trading at a lower price-to-earnings ratio than HilleVax, indicating that it is currently the more affordable of the two stocks.
iTeos Therapeutics currently has a consensus price target of $15.86, indicating a potential upside of 58.10%. HilleVax has a consensus price target of $3.00, indicating a potential upside of 53.85%. Given iTeos Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe iTeos Therapeutics is more favorable than HilleVax.
In the previous week, iTeos Therapeutics had 16 more articles in the media than HilleVax. MarketBeat recorded 18 mentions for iTeos Therapeutics and 2 mentions for HilleVax. HilleVax's average media sentiment score of 1.71 beat iTeos Therapeutics' score of 0.17 indicating that HilleVax is being referred to more favorably in the news media.
Summary
iTeos Therapeutics beats HilleVax on 12 of the 16 factors compared between the two stocks.
Get HilleVax News Delivered to You Automatically
Sign up to receive the latest news and ratings for HLVX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HilleVax Competitors List
Related Companies and Tools
This page (NASDAQ:HLVX) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy HLVX Stock Free HLVX Stock Alerts